Clinical trials: Vaccines
RSV Infection
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1) in…
- Trial name
- NCT03596801
- Testing
- RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Level of Immunity Against Poliovirus Infection
Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals
The purpose of this study was to evaluated the effectiveness of inactivated poliovirus vaccine at a vaccine schedule that is commonly used in developing countries.
- Trial name
- NCT00260312
- Testing
- Inactivated Polio Vaccine given at an accelerated schedule
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pan American Health Organization
Hematologic Diseases
Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation
Aim of this study will evaluate the Impact of Covid-19 vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Stem Cell Transplantation.
- Trial name
- NCT05587881
- Testing
- COVID-19 vaccine(donor), COVID-19 vaccine(patient)
- Where
- China
- Sponsor
- The First Affiliated Hospital of Soochow University
HIV Infections
Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Part A: To compare the safety and immunogenicity of two dose levels of gp120 (CHO) in MF59 emulsion alone or with MTP-PE/MF59 adjuvant, administered at 0, 1, and 6 months.
- Trial name
- NCT00001019
- Testing
- rgp120/HIV-1 SF-2, MTP-PE/MF59
- Where
- 4 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Screening HIV-Infected Patients for Vaccine Studies
This screening study will evaluate potential study volunteers with HIV infection to see if they are suitable candidates for trials of experimental vaccines against HIV (therapeutic), and against other infections (preventive).
- Trial name
- NCT00051519
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diphtheria, Tetanus
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Objectives: To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00802867
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- Where
- 19 sites in United States
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
Phase IV, open, multicenter and single-arm clinical trial designed to evaluate the immunogenicity of the HPV9v vaccine in men with HIV infection (HIV +) who have sex with men (MSM)
- Trial name
- GESIDA10017 (NCT03626467)
- Testing
- HPV9v
- Where
- 3 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Fundacion SEIMC-GESIDA
COVID-19 Pandemic
Fourth BNT162b2 COVID-19 Vaccine Dose
The Omicron variant of concern (VOC) is currently rapidly spreading worldwide, with extremely high transmission rates, with an estimated R of >3.
- Trial name
- NCT05231005
- Testing
- BNT162b2 vaccine
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Glioblastoma Multiforme of Brain
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to…
- Trial name
- NCT04968366
- Testing
- Autologous dendritic cells pulsed with multiple neoantigen peptides., Temozolomide adjuvant chemotherapy
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Beijing Tiantan Hospital
Chronic Liver Disease, Hepatic Carcinoma
A Study to Evaluate Vaccines Against COVID-19 in the Real World
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have afflicted tens of millions of people in a worldwide pandemic.
- Trial name
- NCT04775056
- Where
- Hong Kong
- Volunteers
- healthy volunteers welcome
- Sponsor
- Humanity & Health Medical Group Limited
Healthy Volunteers, Infant
Effects of Shotblocker® and Manual Pressure on Pain
Aim This randomized controlled experimental study was conducted to determine the effect of ShotBlocker® and manual pressure application on pain in the application of Conjugated Pneumococcal Vaccine (PCV).
- Conditions
- Healthy Volunteers, Infant, Vaccine, Pain
- Trial name
- NCT06813729
- Testing
- Shotblocker, Manuel Pressure
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Aydin Adnan Menderes University
Influenza, Avian
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a…
- Trial name
- NCT01052402
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 20 sites in Australia, Finland and 2 more
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Rabies (Healthy Volunteers)
Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
To evaluate the immunogenicity and safety of different post-exposure prophylaxis (PEP) schedules of Sinovac rabies vaccine, in comparison with a marked rabies vaccinein china, in subjects aged 10-60 years old.
- Trial name
- NCT07357545
- Testing
- Sinovac rabies vaccine, Marketed rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 2,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
There is evidence that aluminum phosphate (AlPO4) contained as an adjuvant in conjugate vaccines enhances the immune response in infants. There is no data so far evaluating whether this also applies to adults.
- Trial name
- NCT00269672
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Volunteers
- 915 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous…
- Trial name
- NCT05367895
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Brazil
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Multiple Sclerosis, Covid19
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
This observational study is intended to evaluate the effect of disease modifying therapies on antibody responses to the mRNA-1273 vaccine (Moderna) for COVID-19.
- Trial name
- NCT04834401
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- St. Barnabas Medical Center
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Human Papillomavirus (HPV) Infection, HPV Vaccination Acceptance/Intention
Effect of Different HPV Education Methods on Vaccination Intention in Young Women
Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination.
- Trial name
- NCT07420556
- Testing
- Video-Based HPV Education, Face-to-Face HPV Education
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Emel GÜÇLÜ CİHAN
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline